<DOC>
	<DOCNO>NCT02643251</DOCNO>
	<brief_summary>The study include three ( 3 ) phase : Screening Phase , Treatment Phase , Follow-up Phase . Subjects qualify participate apply study drug foot three time daily record daily pain score use interactive voice response system ( IVRS ) Treatment Phase 12 week . Approximately 100 adult subject randomize receive Clonidine Gel Clonidine Gel Comparator .</brief_summary>
	<brief_title>The Efficacy Safety Clonidine Hydrochloride Topical Gel , v Clonidine Hydrochloride Gel Comparator Treat Painful Diabetic Neuropathy</brief_title>
	<detailed_description>Study CLO-291 randomize , double-blind , comparator-controlled , parallel-group , multicenter study 0.1 % clonidine topical gel ( Clonidine Gel ) treatment pain associate painful diabetic neuropathy . The study include three ( 3 ) phase : Screening Phase , Treatment Phase , Follow-up Phase . Subjects satisfy eligibility criterion apply Clonidine Gel Comparator foot three time daily record daily pain score use interactive voice response system ( IVRS ) . Approximately 100 adult subject randomize receive Clonidine Gel Clonidine Gel Comparator 12 week Treatment Phase .</detailed_description>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Pain</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Clonidine</mesh_term>
	<criteria>1 . Subject fluent English provide write informed consent . 2 . Subject outpatient ≥18 year age time Screening Visit . 3 . Subject Type 1 Type 2 diabetes mellitus hemoglobin A1C value &lt; 10 % stable therapy ( diet , oral antihyperglycemic , and/or insulin ) least six ( 6 ) month prior Screening Visit . 4 . Subject male nonpregnant , nonlactating female . Females must practice acceptable method birth control surgically sterile postmenopausal ( amenorrhea ≥12 month ) . A negative pregnancy test Screening Day 1 visit require female childbearing potential . Doublebarrier method , hormonal contraceptive , abstinence acceptable birth control method study . 5 . Subject chronic pain attributable symmetrical stock distribution neuropathy low extremity least six ( 6 ) month . Pain clearly localized area neuropathy ( foot ) , subject able distinguish target pain painful area condition . 6 . Subject average pain score relevant target pain foot ≥4 11 point numerical pain rating scale previous 24 hour Screening Visit . 7 . Subject meet prespecified , minimum numerical pain rating scale score follow capsaicin skin challenge . 8 . Subject must satisfactorily complete Accurate Pain Reporting Minimizing Placebo Response Training . 9 . Subject must moderate severe pain Screening Runin Phase . 10 . Subjects must 75 110 % compliant application study drug Screening Runin Phase 11 . Subject medically stable least 30 day prior Screening Visit , opinion Investigator , otherwise good general health base medical history , physical examination , electrocardiogram , laboratory evaluation . 1 . Subject neuropathy secondary nondiabetic cause opinion Investigator ( e.g. , vasculitis , familial neuropathy , alcoholism , pernicious anemia , hepatitis , malignancy , chronic inflammatory demyelinate polyneuropathy [ CIDP ] , human immunodeficiency virus [ HIV ] , medicationinduced neuropathy , vitamin B12 deficiency ) . 2 . Subject significant neurological disorder condition might confound assessment painful diabetic neuropathy ( e.g. , stroke distal neurological deficit , mononeuritis multiplex , lumbar radiculopathy ) . 3 . Subject confound disorder determine Algorithm Excluding Disorders Masquerade Painful Diabetic Neuropathy . 4 . Subject sustain pain intensity great bilateral neuropathic pain foot . 5 . Subject use implanted medical device ( e.g. , spinal cord stimulator , intrathecal pump , peripheral nerve stimulator ) treatment pain . 6 . Subject hypotensive rest diastolic blood pressure &lt; 60 mm Hg systolic blood pressure &lt; 90 mm Hg Screening Day 1 Visit . 7 . The subject recent history ( within past 3 month ) current symptom orthostatic hypotension . 8 . Subject history foot toe amputation active foot toe ulcer . 9 . Subject significant unstable medical psychiatric condition , opinion Investigator , would interfere his/her ability participate study . 10 . Subject history substance abuse disorder define Diagnostic Statistical Manual Mental Disorders , 5th Edition , within past year , current evidence substance abuse disorder , receive medical treatment drug abuse , positive urine drug screen nonprescribed substance abuse . 11 . Subject receive receive within 30 day prior Screening Visit prohibit medication anticipate receive start trial new prescription medication painful diabetic neuropathy . Subjects may enrol stable therapy painful diabetic neuropathy . 12 . Subject symptomatic severe coronary insufficiency , clinically significant cardiac conduction disturbance , myocardial infarction ( within last 12 month ) , moderate severe cerebrovascular disease , severe chronic obstructive pulmonary disease ( COPD ) . 13 . Subject estimate creatinine clearance le 50 mL/min ( Cockcroft Gault ) Screening Visit . 14 . Subject serum alanine transaminase ( ALT ) aspartate transaminase ( AST ) &gt; 3.0 time upper limit normal total bilirubin concentration &gt; 2.0 time upper limit normal Screening Visit . 15 . Subject receive investigational drug within 30 day prior Screening Visit . 16 . Subject treat previously clonidine topical gel participate clonidine topical gel clinical study , include Study CLO 290 . 17 . Subject currently take take clonidine ( formulation ) past 4 week . 18 . Subject know hypersensitivity intolerance clonidine . 19 . Subject receive receive ≤7 day prior start Screening Phase `` alternative medicine '' product treatment ( e.g. , acupuncture , naturopathy , homeopathy , etc . ) management pain . 20 . Subject history malignancy within past 5 year except successfully treat nonmetastatic basal cell squamous cell carcinoma skin and/or localize carcinoma situ cervix . 21 . Subject plan surgery course study . 22 . Subject significant skin change physical examination associate either pedal edema venous stasis disease . 23 . Subject dermatologic condition low extremity could affect study drug absorption 24 . Subject current symptom depression Beck Depression Inventory II ( BDI II ) score &gt; 19 Screening Visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Pain</keyword>
	<keyword>Foot Pain</keyword>
	<keyword>Neuropathy</keyword>
</DOC>